Condition
Retinal Drusen
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Completed3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02569892Not ApplicableCompleted
Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration
NCT02960828Not ApplicableUnknown
"Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally" Study
NCT03946085Not ApplicableCompletedPrimary
Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)
NCT01666821Completed
A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population
Showing all 4 trials